WO2001080844A3 - Method of treating dry eye disease with nicotinic acetylcholine receptor agonists - Google Patents

Method of treating dry eye disease with nicotinic acetylcholine receptor agonists Download PDF

Info

Publication number
WO2001080844A3
WO2001080844A3 PCT/US2001/013034 US0113034W WO0180844A3 WO 2001080844 A3 WO2001080844 A3 WO 2001080844A3 US 0113034 W US0113034 W US 0113034W WO 0180844 A3 WO0180844 A3 WO 0180844A3
Authority
WO
WIPO (PCT)
Prior art keywords
analogs
dry eye
acetylcholine receptor
eye disease
nicotinic acetylcholine
Prior art date
Application number
PCT/US2001/013034
Other languages
French (fr)
Other versions
WO2001080844A2 (en
Inventor
Benjamin R Yerxa
Ward M Peterson
Mathew Cowlen
Original Assignee
Inspire Pharmaceuticals Inc
Benjamin R Yerxa
Ward M Peterson
Mathew Cowlen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc, Benjamin R Yerxa, Ward M Peterson, Mathew Cowlen filed Critical Inspire Pharmaceuticals Inc
Priority to AU2001253765A priority Critical patent/AU2001253765A1/en
Priority to AT01927298T priority patent/ATE253912T1/en
Priority to EP01927298A priority patent/EP1214062B1/en
Priority to JP2001577943A priority patent/JP2003531168A/en
Priority to DE60101201T priority patent/DE60101201D1/en
Publication of WO2001080844A2 publication Critical patent/WO2001080844A2/en
Publication of WO2001080844A3 publication Critical patent/WO2001080844A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention provides a method for increasing hydration and lubrication of lacrimal tissues in a subject in need of such treatment. The method comprises administering to the subject a nicotinic acetylcholine receptor agonist such as nicotine and its analogs, transmetanicotine and its analogs, epibatidine and its analogs, lobeline and its analogs, pyridol derivatives, para-alkylthiophenol derivatives, and imidacloprid and its analogs, in an amount effective to stimulate mucus secretion in the lacrimal system. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the formulation include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation, suppository form, or transdermal form. The invention is useful for treating dry eye disease and corneal injury.
PCT/US2001/013034 2000-04-21 2001-04-19 Method of treating dry eye disease with nicotinic acetylcholine receptor agonists WO2001080844A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2001253765A AU2001253765A1 (en) 2000-04-21 2001-04-19 Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
AT01927298T ATE253912T1 (en) 2000-04-21 2001-04-19 USE OF NICOTINERGIC ACETYLCHOLINE RECEPTOR AGONISTS FOR PRODUCING A MEDICATION FOR THE TREATMENT OF KERATOCONJUCTIVITIS SICCA
EP01927298A EP1214062B1 (en) 2000-04-21 2001-04-19 Use of nicotinic acetylcholine receptor agonists for the preparation of a medicament for the treatment of dry eye disease
JP2001577943A JP2003531168A (en) 2000-04-21 2001-04-19 Method for treating dry eye disease with nicotine acetylcholine receptor agonist
DE60101201T DE60101201D1 (en) 2000-04-21 2001-04-19 USE OF NICOTINERGEN ACETYLCHOLIN RECEPTOR AGONISTS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF KERATOCONJUCTIVITIS SICCA

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/557,059 2000-04-21
US09/557,059 US6277855B1 (en) 2000-04-21 2000-04-21 Method of treating dry eye disease with nicotinic acetylcholine receptor agonists

Publications (2)

Publication Number Publication Date
WO2001080844A2 WO2001080844A2 (en) 2001-11-01
WO2001080844A3 true WO2001080844A3 (en) 2002-03-28

Family

ID=24223897

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/013034 WO2001080844A2 (en) 2000-04-21 2001-04-19 Method of treating dry eye disease with nicotinic acetylcholine receptor agonists

Country Status (8)

Country Link
US (1) US6277855B1 (en)
EP (1) EP1214062B1 (en)
JP (1) JP2003531168A (en)
AR (1) AR028026A1 (en)
AT (1) ATE253912T1 (en)
AU (1) AU2001253765A1 (en)
DE (1) DE60101201D1 (en)
WO (1) WO2001080844A2 (en)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223744B2 (en) * 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
US6596725B2 (en) * 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
US6818629B2 (en) 1997-02-10 2004-11-16 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate
US7078391B2 (en) * 1997-02-10 2006-07-18 Inspire Pharmaceuticals, Inc. Method of treating edematous retinal disorders
US6455554B1 (en) * 1999-06-07 2002-09-24 Targacept, Inc. Oxopyridinyl pharmaceutical compositions and methods for use
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
AU2001247474A1 (en) * 2000-03-16 2001-09-24 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
US6596740B2 (en) * 2000-10-24 2003-07-22 Richard L. Jones Nicotine mucosal spray
GB2381750A (en) * 2001-10-10 2003-05-14 Inspire Pharmaceuticals Inc Treatment for enhancing joint lubrication
US6852741B2 (en) * 2001-12-31 2005-02-08 University Of Florida Compositions and methods for treatment of neurological disorders
US6659985B2 (en) 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
US7069084B2 (en) * 2002-06-14 2006-06-27 Seefit Incorporated Method and apparatus for preventing and treating eyelid problems
CA2494506C (en) * 2002-08-02 2009-02-10 Nutraceutical Development Corporation Development of muscle mass in a mammal
US7179481B2 (en) * 2002-09-19 2007-02-20 Kimberly-Clark Worldwide, Inc. Vaginal health products
WO2004037167A2 (en) * 2002-10-18 2004-05-06 Molichem Medicines, Inc. Methods of treating dry eye disease with lantibiotics
UA83011C2 (en) * 2002-11-08 2008-06-10 Зе Маклин Хоспитал Корпорейшн Compounds for treating tobacco dependence and withdrawal syndrome
US7098189B2 (en) * 2002-12-16 2006-08-29 Kimberly-Clark Worldwide, Inc. Wound and skin care compositions
US7056889B2 (en) 2002-12-16 2006-06-06 Kimberly-Clark, Worldwide, Inc. Compounds that bind P2Y2 or P2Y1 receptors
CN100563660C (en) * 2002-12-20 2009-12-02 麦克莱恩医院 The chemical compound that is used for the normalization sleep/wake cycle
KR20050092429A (en) * 2003-01-22 2005-09-21 니찌방 가부시기가이샤 Percutaneous absorption preparation for treating ophthalmic disease, use thereof and method for migration of ophthalmic remedy into topical tissue in eye
US20050013806A1 (en) * 2003-04-04 2005-01-20 Chang Min S. Use of contact lens for corneal cell transplant
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20050208102A1 (en) * 2003-04-09 2005-09-22 Schultz Clyde L Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US9216106B2 (en) * 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US6984628B2 (en) * 2003-07-15 2006-01-10 Allergan, Inc. Ophthalmic compositions comprising trefoil factor family peptides
US20050129710A1 (en) * 2003-10-08 2005-06-16 Renshaw Perry F. Methods of treating psychiatric substance abuse, and other disorders using combinations containing omega-3 fatty acids
US20050113449A1 (en) * 2003-10-08 2005-05-26 Renshaw Perry F. Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
AU2003296968A1 (en) * 2003-12-12 2005-07-14 Richard W. Yee Method and apparatus for preventing and treating eyelid problems
US20060270592A1 (en) * 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
EP1753445A4 (en) * 2004-05-06 2009-05-20 Molichem Medicines Inc Treatment of ocular diseases and disorders using lantibiotic compositions
US7326683B2 (en) * 2004-05-06 2008-02-05 Molichem Medicines, Inc. Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
EP1754491B1 (en) * 2004-05-21 2010-03-03 Senju Pharmaceutical Co., Ltd. Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist
ES2553953T3 (en) * 2004-06-03 2015-12-15 Senju Pharmaceutical Co., Ltd. Drug for the recovery of corneal perception that contains an amide compound
EP1765364A4 (en) * 2004-06-10 2010-09-22 Mclean Hospital Corp Pyrimidines, such as cytidine, in treatments for patients with bipolar disorder
EP1765075A4 (en) * 2004-06-10 2010-11-10 Mclean Hospital Corp Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
US7485666B2 (en) * 2004-06-17 2009-02-03 Kimberly-Clark Worldwide, Inc. Vaginal health products
US7947661B2 (en) * 2004-08-11 2011-05-24 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
WO2006082588A2 (en) * 2005-02-07 2006-08-10 Pharmalight Inc. Method and device for ophthalmic administration of active pharmaceutical ingredients
WO2007013661A1 (en) * 2005-07-26 2007-02-01 Senju Pharmaceutical Co., Ltd. Percutaneously absorbable ophthalmic preparation
FR2889847B1 (en) 2005-08-18 2007-10-05 Sanofi Aventis Sa DERIVATIVES OF 5-PYRIDAZINYL-1-AZABICYCLO [3.2.1] OCTAVE, THEIR PREPARATION IN THERAPEUTICS.
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
WO2007038686A2 (en) 2005-09-27 2007-04-05 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
US20070231360A1 (en) * 2006-03-28 2007-10-04 Minu, L.L.C. Neural conduit agent dissemination
US20070237797A1 (en) * 2006-03-28 2007-10-11 Gholam A. Peyman Neural Conduit Agent Dissemination
US20070297991A1 (en) * 2006-06-23 2007-12-27 Minu, L.L.C. Neural conduit agent dissemination for smoking cessation and other applications
US20080107713A1 (en) * 2006-11-08 2008-05-08 Orilla Werhner C Contact lens as a sustained drug delivery implant
US20080317819A1 (en) * 2007-06-21 2008-12-25 Orilla Werhner C Iop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas
US20090004244A1 (en) * 2007-06-27 2009-01-01 Orilla Werhner C Iris design as a drug depot for zonal drug delivery by contact lens
US20090004245A1 (en) * 2007-06-28 2009-01-01 Orilla Werhner C Use of an iris simulated layer to allow aesthetic appearance drug loaded contact lens
DE102007055046A1 (en) * 2007-11-19 2009-05-28 Fluoron Gmbh infusion
GB0724558D0 (en) * 2007-12-15 2008-01-30 Sharma Anant Optical correction
WO2009139470A1 (en) * 2008-05-16 2009-11-19 学校法人聖マリアンナ医科大学 Pharmaceutical composition for treatment of fibromyalgia
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
KR20110091501A (en) * 2008-10-14 2011-08-11 싸이코제닉스 아이엔씨. Nicotinic acetylcholine receptor ligands and the uses thereof
CA2751271A1 (en) * 2009-02-11 2010-08-19 Heglund, A.S. A composition for buccal absorption of nicotine for the purpose of smoking cessation
TWI578997B (en) 2010-06-04 2017-04-21 輝瑞疫苗有限責任公司 Conjugates for the prevention or treatment of nicotine addiction
US9821159B2 (en) 2010-11-16 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Stimulation devices and methods
RU2013127313A (en) 2010-11-16 2014-12-27 Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити SYSTEMS AND METHODS FOR TREATING A DRY EYE
CN103732611B (en) * 2011-01-10 2016-06-01 伊沃恩有限公司 The purposes of beta-adrenergic inverse agonist for giving up smoking
EP2717888B1 (en) 2011-06-10 2020-09-09 Tissuetech, Inc. Methods of processing fetal support tissues
WO2013032938A1 (en) 2011-08-26 2013-03-07 Tissuetech, Inc. Methods of sterilizing fetal support tissues
US9132193B2 (en) 2012-11-05 2015-09-15 University of Pittsburgh—of the Commonwealth System of Higher Education Use of Slurp1 as an imunomodulatory molecule in the ocular surface
RU2510701C1 (en) * 2012-12-19 2014-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) Method of treating blepharoconjunctival form of dry eye syndrome
WO2014138709A1 (en) * 2013-03-08 2014-09-12 Oculeve, Inc. Devices and methods for treating dry eye in animals
US9717627B2 (en) 2013-03-12 2017-08-01 Oculeve, Inc. Implant delivery devices, systems, and methods
NZ704579A (en) 2013-04-19 2018-10-26 Oculeve Inc Nasal stimulation devices and methods
US9770583B2 (en) 2014-02-25 2017-09-26 Oculeve, Inc. Polymer formulations for nasolacrimal stimulation
US9303013B2 (en) 2014-05-16 2016-04-05 Pfizer Inc. Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction
EP3673952A1 (en) 2014-07-25 2020-07-01 Oculeve, Inc. Stimulation patterns for treating dry eye
DK3209295T4 (en) 2014-10-20 2024-02-26 Oyster Point Pharma Inc METHODS OF TREATMENT OF EYE DISORDERS
US10207108B2 (en) 2014-10-22 2019-02-19 Oculeve, Inc. Implantable nasal stimulator systems and methods
CN107106843A (en) 2014-10-22 2017-08-29 奥库利维公司 Stimulating apparatus and method for treating xerophthalmia
CA2965514A1 (en) 2014-10-22 2016-04-28 Oculeve, Inc. Contact lens for increasing tear production
TW201628633A (en) * 2014-11-05 2016-08-16 組織科技股份有限公司 Compositions and method for promoting nerve growth and regeneration
US10736778B2 (en) 2014-12-31 2020-08-11 Microoptx Inc. Glaucoma treatment devices and methods
BR112017024805B1 (en) * 2015-05-21 2021-09-14 Ophtalmis Monaco COMBINATION OF LIPOIC ACID AND TAURINE AS OSMOPROTECTIVE AGENT
JP2017052723A (en) * 2015-09-10 2017-03-16 株式会社Ｌｔｔバイオファーマ Dry eye improver
CA3000402A1 (en) 2015-09-30 2017-04-06 Microoptx Inc. Dry eye treatment devices and methods
US10426958B2 (en) 2015-12-04 2019-10-01 Oculeve, Inc. Intranasal stimulation for enhanced release of ocular mucins and other tear proteins
US10252048B2 (en) 2016-02-19 2019-04-09 Oculeve, Inc. Nasal stimulation for rhinitis, nasal congestion, and ocular allergies
KR102512777B1 (en) * 2016-04-07 2023-03-23 오이스터 포인트 파마 인코포레이티드 Methods of treating ocular conditions
WO2017178897A2 (en) 2016-04-12 2017-10-19 Arturo Solis Herrera Compositions and methods for treating paranasal mucosa diseases with nicotinic acetylcholine receptor agonists
AU2017260237A1 (en) 2016-05-02 2018-11-22 Oculeve, Inc. Intranasal stimulation for treatment of meibomian gland disease and blepharitis
CN110022755A (en) 2016-12-02 2019-07-16 奥库利维公司 Device and method for xerophthalmia prediction and treatment recommendations
WO2020014217A1 (en) * 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Methods of treating ocular conditions
WO2023279162A1 (en) * 2021-07-07 2023-01-12 University Of Canberra Methods of treatment and inhibition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000119A2 (en) * 1996-07-02 1998-01-08 Boehringer Ingelheim Pharma Kg Applications of active substances affecting the functions of non neuronal acetylcholine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753945A (en) 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US4868154A (en) 1986-02-19 1989-09-19 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with melanocyte stimulating hormones
WO1994005288A1 (en) 1992-08-31 1994-03-17 University Of Florida Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system
US5817679A (en) 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
US5723477A (en) 1994-11-10 1998-03-03 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
US5696166A (en) * 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
US5900407A (en) 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US5830904A (en) 1997-02-05 1998-11-03 University Of Kentucky Research Foundation Lobeline compounds as a treatment for psychostimulant abuse and withdrawal, and for eating disorders
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000119A2 (en) * 1996-07-02 1998-01-08 Boehringer Ingelheim Pharma Kg Applications of active substances affecting the functions of non neuronal acetylcholine

Also Published As

Publication number Publication date
AU2001253765A1 (en) 2001-11-07
US6277855B1 (en) 2001-08-21
EP1214062A2 (en) 2002-06-19
WO2001080844A2 (en) 2001-11-01
EP1214062B1 (en) 2003-11-12
ATE253912T1 (en) 2003-11-15
AR028026A1 (en) 2003-04-23
DE60101201D1 (en) 2003-12-18
JP2003531168A (en) 2003-10-21

Similar Documents

Publication Publication Date Title
WO2001080844A3 (en) Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
ATE428400T1 (en) METHOD FOR TREATING DRY EYE DISEASE USING PURINERGIC RECEPTOR AGONISTS
WO2007022541A3 (en) Method of treating dry eye disease with non-drying antihistamines
US7767698B2 (en) Formulation and use thereof
RU2279871C2 (en) Liquid pharmaceutical composition comprising nicotine for administration into mouth cavity
AU2003243074A1 (en) A buffered, liquid nicotine composition for pulmonary administration
US6448276B1 (en) Method for treating vaginal dryness with nicotinic acetylcholine receptor agonists
AU2020213351B2 (en) Methods of treating ocular conditions
US9642868B2 (en) Topical agents for the treatment of sensory discomfort in the nasal cavity
KR101433396B1 (en) Linseed extract medicament for application to the eye
US20150080442A1 (en) Transmucosal drug delivery system
JP2001302545A (en) Refreshing agent
JP2022514340A (en) Compositions, Devices, and Methods for Treating Overdose and Reward-Based Disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001927298

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 577943

Kind code of ref document: A

Format of ref document f/p: F

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2001927298

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2001927298

Country of ref document: EP